多西他赛加表柔比星用于中晚期乳腺癌新辅助化疗的临床研究

摘要

Objective :To observe the effects and adverse reactions of Neoadjuvant Chemothempy (NCT ) with Docetax-el plus Epirubicin in patients with advanced breast cancer .Methods:40 patients with advanced breast cancer are treated in the department of breast surgery .All patients are treated with Docetaxel 75mg/m2 and Epirubicin 75mg/m2 intrave-nously guttae on 1d .It is going to evaluate the effects and adverse reactions after 3 to 5 periods which are 21 days .Re-sults :The overall response rate(ORR) was 87 .50% ,the complete response(CR) was 40 .00% ,and the partial response (PR) was 47 .50% .The major adverse reactions were alopecia(100 .00% ) ,leukopenia(92 .50% ) ,gastrointestinal reac-tions(60 .00% ) ,thrombocytopenia (47 .50% ) ,cardiac toxicity (27 .50% ) ,and stomatitis (17 .50% ) .Conclusion:It is high efficiency and well tolerated for patients with advanced breast cancer which Docetaxel plus Epirubicin is used to do the Neoadjuvant Chemothempy .It is worthy of clinical promotion .%目的：观察多西他赛联合表柔比星的新辅助化疗（NCT ）方案在中晚期乳腺癌治疗中的疗效及毒副反应。方法：选择我院乳腺外科治疗的中晚期乳腺癌患者40例。所有患者接受多西他赛75mg/m2和表柔比星75mg/m2，静脉滴入1d。每21d为1个周期，行3～5周期后评价疗效和毒副反应。结果：（1）RR为87．50％，其中CR为40．00％， PR为47．50％。（2）不良反应主要以脱发（100．00％）、白细胞减少（92．50％）及胃肠道不适（60．00％）多见，其他均有不同程度的血小板下降（47．50％）、心脏毒性（27．50％）及口腔黏膜炎（17．50％）。结论：多西他赛联合表柔比星对中晚期乳腺癌进行NCT ，有效率高，治疗耐受性好，值得临床推广运用。